BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) sotorasib (AMG 510) lifileucel (LN-144, contego, TILs) omburtamab, 124I-8H9 (B7-H3...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...PDCD1) (CD279) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) CD70 (CD27L) Splice variant v6 of CD44 (CD44v6) B7-H3 (CD276) AXL...
BioCentury | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

...MacroGenics plans to begin a Phase II trial this year of the Fc-optimized mAb against B7-H3...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...HER3; ERBB3; EGFR3) Breast cancer, Non-small cell lung cancer (NSCLC) Ph I DS-7300 ADC targeting B7-H3 (CD276)...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

...development. The major outstanding question for B7-H3 CAR Ts is whether the differential expression of B7-H3...
...and Lyell declined to disclose its development plans. Table: Therapies targeting B7-H3 The PD-L1-related checkpoint B7-H3 (CD276)...
...NASDAQ:MGNX) MGC018 B7-H3 antibody-drug conjugate (ADC) B7-H3-expressing solid tumors Preclin Stanford University B7-H3 CAR T Anti-B7-H3...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Cancer

...INDICATION: Bone cancer; sarcoma; brain cancer Mouse studies suggest CAR T cells targeting B7-H3 could help...
...from 388 patients with pediatric solid tumors and brain tumors, 325 (84%) were positive for B7-H3...
...tumors. MacroGenics also has a B7-H3 antibody-drug conjugate in preclinical testing for solid tumors. TARGET/MARKER/PATHWAY: B7-H3 (CD276)...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

...dark green ) or T cells ( teal ), which suppress activated T cells. B7-H3 (CD276)...
BioCentury | Dec 14, 2018
Clinical News

FDA places hold on Phase I trials of MacroGenics' bispecific molecule due to hepatic events

...is evaluating MGD009 plus anti-PD-1 mAb MGA012. MDG009 is a bispecific molecule targeting CD3 and B7-H3 (CD276)...
...Safety Status: Phase I clinical hold Milestone: NA Meghan Sullivan MGA012 MGD009, B7-H3 x CD3 DART molecule Incyte Corp. MacroGenics Inc. B7-H3 (CD276) CD3 Programmed...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...North Carolina at Chapel Hill describes a CAR T cell construct targeting the checkpoint protein B7-H3...
...MDSCs) expressing the target ( No. 701 ). At least four companies have products targeting B7-H3...
...Center, Houston, Texas WindMIL Therapeutics Inc., Baltimore, Md. Targets AICDA (AID) - Activation-induced cytidine deaminase B7-H3 (CD276)...
BioCentury | Sep 28, 2018
Financial News

First-day pop for Y-mAbs after upsized $110M IPO

...neuroblastoma indications. The molecules are naxitamab, which targets ganglioside GD2 (GD2); and I-omburtamab, which targets B7-H3 (CD276)...
...Y-mAbs Therapeutics Inc. (NASDAQ:YMAB), New York, N.Y. Sandi Wong naxitamab (hu3F8) omburtamab, 124I-8H9 (B7-H3), burtomab (8h9) Y-mAbs Therapeutics Inc. B7-H3 (CD276) Ganglioside...
Items per page:
1 - 10 of 34